Danske Bank A S Invests $13.11 Million in DaVita Inc. $DVA

Danske Bank A S acquired a new stake in shares of DaVita Inc. (NYSE:DVA) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 58,943 shares of the company’s stock, valued at approximately $13,114,000. Danske Bank A S owned approximately 0.09% of DaVita as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in DVA. Root Financial Partners LLC raised its holdings in DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after purchasing an additional 105 shares in the last quarter. Caitlin John LLC purchased a new position in shares of DaVita in the fourth quarter worth $34,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita in the 2nd quarter valued at $43,000. Sankala Group LLC purchased a new position in DaVita in the 4th quarter worth $39,000. Finally, iSAM Funds UK Ltd purchased a new stake in DaVita during the 3rd quarter valued at about $46,000. 90.12% of the stock is owned by institutional investors.

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.90% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on DVA shares. Oppenheimer set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. UBS Group upped their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Truist Financial reduced their price target on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Finally, TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and upped their price objective for the stock from $201.00 to $220.00 in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $221.75.

DaVita Stock Performance

DVA opened at $175.54 on Friday. The company has a fifty day moving average of $215.64 and a two-hundred day moving average of $181.58. The stock has a market capitalization of $11.20 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 0.59 and a beta of 0.88. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same period in the prior year, the company posted $2.95 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.